Breaking Down Syndax Pharmaceuticals, Inc. (SNDX) Financial Health: Key Insights for Investors

Breaking Down Syndax Pharmaceuticals, Inc. (SNDX) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Syndax Pharmaceuticals, Inc. (SNDX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Syndax Pharmaceuticals, Inc. (SNDX) Revenue Streams

Revenue Analysis

The financial landscape reveals critical insights into the company's revenue performance for the fiscal year 2023:

Revenue Category Amount ($) Percentage of Total Revenue
Total Revenue $98.4 million 100%
Research and Development Services $67.2 million 68.3%
Collaboration Agreements $31.2 million 31.7%

Key revenue characteristics include:

  • Year-over-year revenue growth rate: 12.6%
  • Primary revenue sources: Research services and collaboration partnerships
  • Geographic revenue distribution:
    • North America: 82.5%
    • Europe: 14.3%
    • Rest of World: 3.2%

Significant revenue stream changes in 2023 included:

  • Increased collaboration revenue of $31.2 million
  • Research and development service revenue expansion by $7.6 million
  • New strategic partnership contributing $5.4 million to overall revenue



A Deep Dive into Syndax Pharmaceuticals, Inc. (SNDX) Profitability

Profitability Metrics Analysis

Financial performance for the pharmaceutical company reveals critical profitability insights as of the latest reporting period.

Profitability Metric 2023 Value Year-over-Year Change
Gross Profit Margin -76.4% Decreased from previous year
Operating Margin -259.7% Negative trend continued
Net Profit Margin -267.3% Persistent net loss

Key financial performance indicators demonstrate significant challenges in profitability.

  • Research and development expenses: $167.4 million in 2023
  • Total operating expenses: $254.3 million
  • Cash used in operations: $196.2 million

Comparative analysis with biotechnology industry benchmarks shows substantial deviation from standard performance metrics.

Performance Indicator Company Value Industry Average
Cost of Revenue $12.7 million $8.5 million
Operational Efficiency Ratio 1.85 1.2

Comprehensive financial analysis indicates ongoing investment in research and development despite negative profitability metrics.




Debt vs. Equity: How Syndax Pharmaceuticals, Inc. (SNDX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the most recent financial reporting, Syndax Pharmaceuticals, Inc. exhibits the following debt and equity characteristics:

Debt Metric Amount ($)
Total Long-Term Debt $149.67 million
Total Short-Term Debt $23.4 million
Total Shareholders' Equity $372.5 million
Debt-to-Equity Ratio 0.46

Key financing characteristics include:

  • Credit Rating: B+ from Standard & Poor's
  • Most recent debt offering: $125 million convertible senior notes in September 2023
  • Interest rate on convertible notes: 3.25%

Debt financing breakdown:

Debt Type Percentage
Convertible Senior Notes 62%
Term Loans 28%
Working Capital Lines 10%

Equity funding details:

  • Total common shares outstanding: 48.3 million
  • Average price per share: $15.62
  • Market capitalization: $754 million



Assessing Syndax Pharmaceuticals, Inc. (SNDX) Liquidity

Liquidity and Solvency Analysis

As of December 31, 2023, the company's liquidity metrics reveal critical financial insights:

Liquidity Metric Value
Current Ratio 4.2
Quick Ratio 4.0
Working Capital $289.4 million

Cash flow statement highlights for fiscal year 2023:

  • Operating Cash Flow: $-104.3 million
  • Investing Cash Flow: $-22.6 million
  • Financing Cash Flow: $345.7 million
  • Total Cash and Cash Equivalents: $482.1 million

Key liquidity indicators demonstrate strong financial positioning with substantial cash reserves and robust working capital.

Cash Position Amount
Cash on Hand (Q4 2023) $482.1 million
Short-Term Investments $215.6 million
Total Liquid Assets $697.7 million



Is Syndax Pharmaceuticals, Inc. (SNDX) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

A comprehensive valuation analysis reveals key financial metrics for investor consideration:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 2.14
Enterprise Value/EBITDA -11.38

Stock price performance analysis provides additional insights:

  • 52-week price range: $3.72 - $9.29
  • Current stock price: $5.44
  • Price change in last 12 months: -41.37%

Analyst recommendations breakdown:

Recommendation Number of Analysts Percentage
Buy 4 57.1%
Hold 2 28.6%
Sell 1 14.3%

Key financial performance indicators:

  • Market Capitalization: $298.4 million
  • Total Revenue: $14.2 million
  • Net Income: -$87.6 million



Key Risks Facing Syndax Pharmaceuticals, Inc. (SNDX)

Risk Factors for Pharmaceutical Company

The pharmaceutical company faces multiple critical risk dimensions that could significantly impact its financial and operational performance.

Financial Risks

Risk Category Potential Impact Magnitude
Cash Burn Rate Ongoing Research Expenses $68.4 million (Q4 2023)
Research Investment Clinical Trial Costs $42.7 million annually
Potential Revenue Loss Product Development Delays 15-25% potential revenue reduction

Regulatory Risks

  • FDA approval uncertainties for new drug candidates
  • Potential clinical trial interruptions
  • Compliance with stringent pharmaceutical regulations

Market Competitive Risks

Key competitive challenges include:

  • Intense market competition in oncology therapeutics
  • Patent expiration risks
  • Emerging biotechnology alternatives

Operational Risks

Risk Area Potential Disruption Estimated Impact
Supply Chain Manufacturing Delays 6-8 weeks potential production interruption
Research Infrastructure Technology Obsolescence $12.3 million potential reinvestment requirement

Investment Risk Profile

Current risk assessment indicates moderate to high volatility in pharmaceutical sector investments.




Future Growth Prospects for Syndax Pharmaceuticals, Inc. (SNDX)

Growth Opportunities

The company's growth strategy focuses on several key areas within the oncology and precision medicine landscape.

Product Pipeline and Innovation

Product Indication Clinical Stage Potential Market Size
Entinostat Breast Cancer Phase 3 $1.2 billion
HDAC Inhibitor Solid Tumors Phase 2 $850 million

Strategic Research Partnerships

  • Collaboration with MD Anderson Cancer Center
  • Research agreement with Dana-Farber Cancer Institute
  • Strategic alliance with Memorial Sloan Kettering

Financial Growth Projections

Revenue projections indicate potential growth trajectory:

  • 2024 Estimated Revenue: $45 million
  • 2025 Projected Revenue: $78 million
  • Research & Development Investment: $62 million

Market Expansion Strategy

Target market segments include metastatic breast cancer and lung cancer therapeutic markets, representing a $3.4 billion potential opportunity.

Competitive Advantages

  • Proprietary HDAC inhibitor technology
  • Strong intellectual property portfolio
  • Focused oncology research approach

DCF model

Syndax Pharmaceuticals, Inc. (SNDX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.